


De-Implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum

NOT-CA-20-021
Notice of Special Interest (NOSI)
Pre-Application Funding Webinar
National Cancer Institute

Using WebEx and Webinar Training Logistics



- All lines will be in listen-only mode
- Submit questions at any time during the presentation. Type into the Q&A Panel and select Host
- A moderator will ask the question on your behalf during the Q&A portions of the webinar
- This webinar is being recorded and will be posted at a later date

Webinar Presenters



Erica S. Breslau, PhD, MPH
Program Director
Health Systems and Interventions Research Branch
Healthcare Delivery Research Program
Division of Cancer Control and Population Sciences
breslaue@mail.nih.gov



Wynne E. Norton, PhD
Program Director
Implementation Science
Division of Cancer Control and Population Sciences
wynne.norton@nih.gov

Webinar Overview

1. Overview of NIH Notice of Special Interest (NOSI)
2. Background, Purpose of NCI De-implementation NOSI, [NOT-CA-20-021](#)
3. Research Objectives, Select Research Areas
4. Application and Submission Information
5. Questions

NIH Notice of Special Interest (NOSI)

- Notice posted in the NIH guide that institutes and centers can use to share and update research priorities.
- NOSIs succinctly highlight a specific topic of interest (e.g., specific area of research or program).
- NOSIs direct applicants to one or more active FOAs for submission of applications for the initiative described.
- NOSIs: Standing study section, no set-aside funds, NOSIs slowly replacing program announcements (PAs).
- See [NOT-OD-19-107](#) and [FAQs](#) for details on NIH NOSIs.

NCI De-Implementation NOSI

- [NOT-CA-20-021](#)
- De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum
- Issued January 6th, 2020
- Only allows for applications that use R01 mechanism
- Only supported by NCI
- *Definition:* De-implementation research is broadly defined as the scientific study of factors, processes, and strategies for reducing, replacing, or stopping the use of ineffective or low-value clinical practices in healthcare delivery settings.

Background

- Use of ineffective or low-value clinical practices may have negative impact on patients, healthcare providers, healthcare teams, healthcare organizations, and healthcare systems.
- Ineffective or low-value cancer-related practices are common along cancer care continuum.
- Research on de-implementation of ineffective or low-value practices is understudied.
- A better understanding of de-implementation is necessary to optimize patient health outcomes and maximize use of limited resources.

Purpose

- Highlight interest in investigator-initiated grant applications that propose to study the de-implementation of ineffective or low-value clinical practices, programs, treatments, or interventions (“practices”) along the cancer care continuum from detection to end-of-life.
- Studies should propose to use rigorous methods and study designs to understand and/or affect de-implementation of ineffective or low-value clinical practices in cancer care.

Research Objectives

- Broaden and deepen scientific understanding of de-implementation.
- Exploratory and/or hypothesis-driven R01 studies.
- Variety of study designs (e.g., observational, experimental, quasi-experimental, natural experiments, pragmatic randomized clinical trials).
- Variety of research methods (e.g., qualitative, quantitative, mixed methods).
- Studies must focus on one or more phases of the cancer care continuum: detection, diagnosis, treatment, survivorship, and/or end-of-life.
- Studies are encouraged to examine multilevel aspects of de-implementation.

Select Research Areas

- Research encouraged through this NOSI includes (but is not limited to) studies that propose to:
 - Explore multilevel factors associated with de-implementation.
 - Understand de-implementation predictors, processes, and outcomes.
 - Understand how de-implementation may differ by type of ineffective or low-value clinical practice, phase along cancer care continuum, or type of action.
 - Develop and validate instruments to measure de-implementation.
 - Develop and test multilevel strategies to facilitate de-implementation.

Application Process

- De-implementation of Ineffective or Low-value Clinical Practices along the Cancer Care Continuum, [NOT-CA-20-021](#)
- Must submit application to one of four R01 funding opportunity announcements (FOAs) listed in the de-implementation NOSI announcement:
 - [PAR-18-869](#)
 - [PAR-18-559](#)
 - [PAR-19-274](#)
 - [PA-19-056](#)
- Applications in response to this NOSI cannot be submitted to other grant mechanisms (e.g., R21, R03) or FOAs not listed above.

Details on FOAs for De-Implementation NOSI Application

Activity Code	FOA Number	FOA Title	First Available Due Date
R01	<u>PAR-18-869</u>	Modular R01s in Cancer Control and Population Sciences R01 Clinical Trial <i>Optional</i>	March 6 th , 2020
R01	<u>PAR-18-559</u>	Cancer Prevention and Control Clinical Trials Grant Program R01 Clinical Trial <i>Required</i>	June 5 th , 2020
R01	<u>PAR-19-274</u>	Dissemination and Implementation Research in Health R01 Clinical Trial <i>Optional</i>	June 5 th , 2020
R01	<u>PA-19-056</u>	NIH Research Project Grant Parent R01 Clinical Trial <i>Not Allowed</i>	June 5 th , 2020

Application Process: Important Dates

- NOSI expiration date: May 10th, 2022
- Earliest submission date: March 6th, 2020 (PAR-18-869 *only*)
- Application due dates:
 - [PAR-18-869](#) See notice for due dates
 - [PAR-18-559](#) Standard application due dates
 - [PAR-19-274](#) Standard application due dates
 - [PA-19-056](#) Standard application due dates
- Applicants may submit to any of the reissuances of above announcements through NOSI expiration date.

Application Requirements

- All instructions in the SF424 (R&R) application guide and the FOA used for submission must be followed.
- Applicants must include “NOT-CA-20-021” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form.
- Applications without the correct Agency Routing Identifier information will not be considered for the NOSI initiative.
- Applications nonresponsive to terms of this NOSI will not be considered for the NOSI initiative.

Review Criteria

- Standard review criteria as described in eligible R01 FOAs.
- Scored review criteria: Significance, Innovation, Investigators, Approach, Environment.
- Additional review criteria: Study timeline (for clinical trials), protections for human subjects, inclusion, vertebrate animals, biohazards.
- Additional review considerations: Check FOA to see resource sharing plan requirements (e.g., data sharing plan) or other listed requirements.

Common Question #1

- **Where can I find more information about *NIH NOSIs*?**
- [NOT-OD-19-107](#), NIH Expanding Usage of Notices of Special Interest (NOSI). Issued by NIH, June 14th, 2019.
- [NIH NOSI FAQs](#): What is a NOSI? How does NIH distinguish applications submitted in direct response to an FOA from applications submitted in response to a NOSI that uses that FOA for submission? Can I include an assignment request when I submit my application to a NOSI?

Common Question #2

- What is the *cancer care continuum* and how does that relate to my application?
- For purposes of this NOSI, the cancer care continuum includes the following phases: detection, diagnosis, treatment, survivorship, and end-of-life care.
- Applications must focus on one or more phases of the cancer care continuum listed above.
- Applications that focus on other aspects of the cancer continuum (e.g., etiology, prevention) are considered non-responsive to this NOSI.

Common Question #3

- What are *clinical practices*?
- For purposes of this NOSI, clinical practices are practices, programs, treatments, or interventions delivered along the cancer care continuum from detection to end-of-life.

Common Question #4

- What clinical practices along the cancer care continuum are considered to be *ineffective or low-value*?
- Determination made by research team.
- Application should explain why the proposed clinical practice is considered ineffective or low-value.
- Potential resources for identifying candidate clinical practices:
 - Choosing Wisely® recommendations
 - Clinical practice guidelines
 - Professional society recommendations

Resources

- A recording of this webinar will be posted on our website shortly.
- NCI Healthcare Delivery Research Program (HDRP):
<https://healthcaredelivery.cancer.gov/>
- NCI Implementation Science (IS):
<https://cancercontrol.cancer.gov/IS/>

Submission Inquiries

- Scientific/Research Contacts:
 - Erica S. Breslau (HDRP), breslaue@mail.nih.gov
 - Wynne E. Norton (IS), wynne.norton@nih.gov

- Financial/Grants Management Contact:
 - Carol Perry, perryc@mail.nih.gov

Webinar Audience Questions

Please type your question in the Q&A section on WebEx.



**NATIONAL
CANCER
INSTITUTE**

www.cancer.gov

www.cancer.gov/espanol